{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:03:58Z","timestamp":1793271838842,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Scientific Research Fund of Hebei Provincial Health and Family Planning Commission","award":["20220421"],"award-info":[{"award-number":["20220421"]}],"id":[{"id":"https:\/\/ror.org\/01pktrj81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"abstract":"<jats:p>Pemphigus is a rare yet serious autoimmune skin disease. This study aimed to identify the drugs most commonly associated with pemphigus risk using the Federal drug administration adverse event reporting system (FAERS) database. Data on drugs and adverse events between 2004 and the second quarter of 2024 were obtained from the FAERS database. The medical dictionary for regulatory activities (MedDRA) was used to identify pemphigus cases, whereas the DrugBank database was used to determine the generic names of the medications. Four signal quantification methods were used for the analysis: odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, and empirical Bayesian geometric mean. Additionally, the timing of drug-induced pemphigus was calculated using Weibull shape parameters. Finally, potential factors affecting pemphigus were identified in the FAERS database using univariate and multivariate logistic regression analyses. Of the 7315 adverse event reports linked to pemphigus, diclofenac sodium was involved in 1227 cases, which was the highest number. Disproportionality analysis Disproportionality analysis identified the top 5 drugs that caused adverse reactions: diclofenac sodium, abatacept, tocilizumab, and alendronate sodium. Based on the time to onset of drug-induced pemphigus, the Weibull shape parameter (0.60) indicated that pemphigus induced by this class of drugs was classified as an early failure. Seven independent risk factors related to drugs were identified through multivariable analysis, including diclofenac sodium, abatacept, tocilizumab, alendronate sodium, secukinumab, cetirizine, and chlorhexidine, odds ratio\u2005&gt;1 for each. FAERS database was analyzed to identify drugs with strong pemphigus signals, which can be used as a guide for standardizing drug use in clinical practice.<\/jats:p>","DOI":"10.1097\/md.0000000000044497","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:01:32Z","timestamp":1757970092000},"page":"e44497","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Exploring drug-induced pemphigus findings from the FDA adverse event reporting system database"],"prefix":"10.1097","volume":"104","author":[{"given":"Yandong","family":"Niu","sequence":"first","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatric Surgery, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0971-1670","authenticated-orcid":false,"given":"Xinsuo","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260923","doi-asserted-by":"crossref","first-page":"1326359","DOI":"10.3389\/fmed.2023.1326359","article-title":"Pemphigus: trigger and predisposing factors.","volume":"10","author":"Moro","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"R2-20260923","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12026-018-8986-7","article-title":"Pemphigus group: overview, epidemiology, mortality, and comorbidities.","volume":"66","author":"Kridin","year":"2018","journal-title":"Immunol Res"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.clindermatol.2013.01.004","article-title":"Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies.","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin Dermatol"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000057886","article-title":"Long-term efficacy of dexamethasone-cyclophosphamide pulse therapy in pemphigus.","volume":"204","author":"Kanwar","year":"2002","journal-title":"Dermatology"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"e166357","DOI":"10.1172\/JCI166357","article-title":"Microenvironmental network of clonal CXCL13+CD4+ T cells and Tregs in pemphigus chronic blisters.","volume":"133","author":"Han","year":"2023","journal-title":"J Clin Invest"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.intimp.2005.11.002","article-title":"Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.","volume":"6","author":"Daoud","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1159\/000530121","article-title":"The global incidence rate of pemphigus vulgaris: a systematic review and meta-analysis.","volume":"239","author":"Zhao","year":"2023","journal-title":"Dermatology"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"107299","DOI":"10.1016\/j.intimp.2020.107299","article-title":"Drug-induced pemphigus: a systematic review of 170 patients.","volume":"92","author":"Ghaedi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"R9-20260923","doi-asserted-by":"crossref","DOI":"10.7754\/Clin.Lab.2023.230722","article-title":"Positive herpesvirus IgG antibodies in lung cancer patients finally proved as drug-induced pemphigus.","volume":"70","author":"Jiang","year":"2024","journal-title":"Clin Lab"},{"key":"R10-20260923","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/bjd.17640","article-title":"Long noncoding RNA polymorphisms influence susceptibility to endemic pemphigus foliaceus.","volume":"181","author":"Lobo-Alves","year":"2019","journal-title":"Br J Dermatol"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2133.2003.05209_10.x","article-title":"Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab).","volume":"148","author":"Herrmann","year":"2003","journal-title":"Br J Dermatol"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"adv00224","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid.","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12941-020-00388-6","article-title":"Features and associated factors of bacterial skin infections in hospitalized patients with pemphigus: a single-center retrospective study.","volume":"19","author":"Li","year":"2020","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"R14-20260923","first-page":"360","article-title":"Bullous pemphigoid induced by hydrochlorothiazide therapy.","volume":"13","author":"Warner","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.2174\/1381612821666150915105738","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) induced dyspepsia.","volume":"21","author":"Yap","year":"2015","journal-title":"Curr Pharm Des"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/ACI.0000000000000461","article-title":"Interaction between foods and nonsteroidal anti-inflammatory drugs and exercise in the induction of anaphylaxis.","volume":"18","author":"Bartra","year":"2018","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"16202","DOI":"10.1038\/s41598-024-67209-0","article-title":"Cardiac adverse events associated with lacosamide: a disproportionality analysis of the FAERS database.","volume":"14","author":"Yang","year":"2024","journal-title":"Sci Rep"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the Food and Drug Administration.","volume":"23","author":"Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1529-8019.2009.01233.x","article-title":"Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA).","volume":"22","author":"Weaver","year":"2009","journal-title":"Dermatol Ther"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018.","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system.","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"119010","DOI":"10.1016\/j.jep.2024.119010","article-title":"Ginkgo biloba extract safety: insights from a real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events.","volume":"337","author":"Yao","year":"2025","journal-title":"J Ethnopharmacol"},{"key":"R24-20260923","first-page":"e934482","article-title":"Development of a predictive nomogram for estimating medication nonadherence in hemodialysis patients.","volume":"28","author":"Wang","year":"2022","journal-title":"Med Sci Monit"},{"key":"R26-20260923","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.2169\/internalmedicine.4646-20","article-title":"Drug-induced bullous pemphigoid and lupus erythematosus occurring under anti-TNF-\u03b1 and IL-6 therapy in a patient with rheumatoid arthritis.","volume":"59","author":"Yoshikawa","year":"2020","journal-title":"Intern Med"},{"key":"R27-20260923","doi-asserted-by":"crossref","first-page":"e36988","DOI":"10.1097\/MD.0000000000036988","article-title":"Adalimumab induced exacerbation of psoriasis in patients with combined pemphigus: a case report.","volume":"103","author":"Yao","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R28-20260923","doi-asserted-by":"crossref","first-page":"e442","DOI":"10.1111\/ajd.13339","article-title":"Pemphigus foliaceous triggered by topical diclofenac.","volume":"61","author":"O\u2019Grady","year":"2020","journal-title":"Australas J Dermatol"},{"key":"R29-20260923","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1365-4632.2010.04706.x","article-title":"Drug-induced pemphigus after six years of treatment with phenytoin and carbamazepine.","volume":"51","author":"Tang","year":"2012","journal-title":"Int J Dermatol"},{"key":"R30-20260923","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/archderm.1987.01660330026002","article-title":"Penicillamine-induced bullous pemphigoid-like eruption.","volume":"123","author":"Brown","year":"1987","journal-title":"Arch Dermatol"},{"key":"R31-20260923","first-page":"108","article-title":"Amoxicillin\/clavulanic acid-induced pemphigus vulgaris: case report.","volume":"20","author":"Baroni","year":"2012","journal-title":"Acta Dermatovenerol Croat"},{"key":"R32-20260923","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1111\/j.1365-2230.2008.03181.x","article-title":"Pemphigus-like lesions induced by imiquimod.","volume":"34","author":"Bauza","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"R33-20260923","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2230.2010.03918.x","article-title":"Reversible relapse of pemphigus foliaceus triggered by topical imiquimod suggests that Toll-like receptor 7 inhibitors may be useful treatments for pemphigus.","volume":"36","author":"Sebaratnam","year":"2011","journal-title":"Clin Exp Dermatol"},{"key":"R34-20260923","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.clindermatol.2011.01.016","article-title":"Drug-induced pemphigus.","volume":"29","author":"Brenner","year":"2011","journal-title":"Clin Dermatol"},{"key":"R35-20260923","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00002018-200023040-00002","article-title":"Drug-induced rheumatic disorders: incidence, prevention and management.","volume":"23","author":"Vergne","year":"2000","journal-title":"Drug Saf"},{"key":"R36-20260923","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12016-018-8672-5","article-title":"Sex and management of rheumatoid arthritis.","volume":"56","author":"Favalli","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"R37-20260923","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1200\/JOP.19.00751","article-title":"Pembrolizumab-induced bullous pemphigoid treated with rituximab.","volume":"16","author":"Sharma","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"R38-20260923","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1111\/ijd.16678","article-title":"Efficacy and safety of biological agents for pemphigoid: a systematic review and meta-analysis.","volume":"62","author":"Lin","year":"2023","journal-title":"Int J Dermatol"},{"key":"R39-20260923","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid.","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol"},{"key":"R40-20260923","doi-asserted-by":"crossref","first-page":"884931","DOI":"10.3389\/fimmu.2022.884931","article-title":"Rituximab - progress but still not a final resolution for pemphigus patients: clinical report from a single center study.","volume":"13","author":"Mi\u0161e","year":"2022","journal-title":"Front Immunol"},{"key":"R41-20260923","doi-asserted-by":"crossref","first-page":"e8541","DOI":"10.1002\/ccr3.8541","article-title":"Rituximab-induced psoriasis in a patient with pemphigus vulgaris: a case report and literature review.","volume":"12","author":"Ghadirzade Arani","year":"2024","journal-title":"Clin Case Rep"},{"key":"R42-20260923","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1111\/1346-8138.16367","article-title":"Rituximab-induced psoriasis in a patient with pemphigus foliaceous: a case report and literature review.","volume":"49","author":"Charoenpipatsin","year":"2022","journal-title":"J Dermatol"},{"key":"R43-20260923","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-2133.2012.11040.x","article-title":"Association between HLA-DRB1 polymorphisms and pemphigus vulgaris: a meta-analysis.","volume":"167","author":"Yan","year":"2012","journal-title":"Br J Dermatol"},{"key":"R44-20260923","doi-asserted-by":"crossref","first-page":"886","DOI":"10.15537\/smj.2018.9.23156","article-title":"Relationship between human leukocyte antigen DRB1 and psoriasis in Iraqi patients.","volume":"39","author":"Zalzala","year":"2018","journal-title":"Saudi Med J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:54Z","timestamp":1790186574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":42,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044497","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}